Concourse Financial Group Securities’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-5
Closed -$1.69K 2382
2024
Q2
$1.59K Hold
5
﹤0.01% 2065
2024
Q1
$1.15K Hold
5
﹤0.01% 2120
2023
Q4
$1.1K Buy
5
+2
+67% +$461 ﹤0.01% 2102
2023
Q3
$677 Buy
+3
New +$691 ﹤0.01% 2145
2022
Q4
Sell
-4
Closed -$1.01K 2354
2022
Q3
$1K Sell
4
-140
-97% -$31.3K ﹤0.01% 1937
2022
Q2
$34K Sell
144
-7
-5% -$1.42K ﹤0.01% 1248
2022
Q1
$27K Buy
151
+1
+0.7% +$191 ﹤0.01% 1396
2021
Q4
$32K Sell
150
-4
-3% -$785 ﹤0.01% 1477
2021
Q3
$28K Sell
154
-2
-1% -$394 ﹤0.01% 1543
2021
Q2
$28K Sell
156
-2
-1% -$381 ﹤0.01% 1537
2021
Q1
$26K Sell
158
-13
-8% -$2.17K ﹤0.01% 1486
2020
Q4
$26K Sell
171
-5
-3% -$656 ﹤0.01% 1374
2020
Q3
$18K Buy
+176
New +$19.3K ﹤0.01% 1405
2020
Q1
Sell
-43
Closed -$4.09K 2325
2019
Q4
$4K Hold
43
﹤0.01% 1717
2019
Q3
$3K Sell
43
-64
-60% -$5.15K ﹤0.01% 1478
2019
Q2
$8K Buy
107
+24
+29% +$2.24K ﹤0.01% 1580
2019
Q1
$9K Buy
83
+11
+15% +$1.28K ﹤0.01% 1561
2018
Q4
$7K Buy
72
+31
+76% +$3.59K ﹤0.01% 1555
2018
Q3
$5K Buy
+41
New +$5.07K ﹤0.01% 1416

Other funds holding UTHR

Concourse Financial Group Securities's UTHR Position: Q3 2024 in Review

Concourse Financial Group Securities sold out of United Therapeutics (UTHR) in Q3 2024, closing a stake of 5 shares — an estimated $1.69K sold.

Concourse Financial Group Securities first reported a position in UTHR in Q3 2018 and held it in 19 quarters. The position peaked at $34K in Q2 2022. 625 funds tracked by Wall St. Rank hold UTHR as of Q3 2024.

  • Concourse Financial Group Securities reported no remaining United Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Concourse Financial Group Securities sold 5 United Therapeutics shares in Q3 2024, an estimated $1.69K.
  • Concourse Financial Group Securities first reported a position in United Therapeutics in Q3 2018 and held it in 19 quarters.
  • Concourse Financial Group Securities's United Therapeutics position peaked at $34K in Q2 2022.
  • 625 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2024.

Based on Concourse Financial Group Securities's 13F filing for Q3 2024, filed 10 Oct 2024.